Enter your keyword

A Focused Portfolio Addressing Areas of Unmet Need

Development Pipeline

OXi4503

Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS)

OXi4503 + cytarabine (OX1222)

Phase 1/2

Preclinical programs are being conducted in the following areas: